Scientific &
jurisdictional notice.

A thoughtful approach to the future

Noah Thera explores the intersection of longevity science, precision wellness and the possibilities opened by advanced computation. This website and The Continuum Letter share general educational information, brand perspectives and future ambitions. They do not provide a personal diagnosis, prescription or individual medical advice. Decisions about medical care belong with appropriately qualified professionals who can assess your circumstances.

Understanding the science

References to stem cells, nPSC, genomic analysis, gene editing, cellular rejuvenation and AI describe distinct areas of scientific enquiry. “nPSC” is used here within Noah Thera’s own research narrative and terminology. It should not be interpreted as a regulatory classification or approval. Findings about a particular cell type, model, experimental system or third-party product do not establish the performance of a Noah Thera service.

Research findings are specific to their methods, population and measured outcomes. Computer predictions, laboratory observations and animal studies are different from clinical evidence in people. References to healthy longevity and age reversal describe scientific aims and directions, not a promise to reverse an individual’s age, prevent disease or deliver a particular lifespan. Individual outcomes vary.

AI and in silico models can support analysis and research prioritisation. Their outputs require appropriate validation and professional interpretation. References to artificial general intelligence or technological singularity express a future-oriented perspective; they do not describe a current Noah Thera clinical capability or a guaranteed development timetable.

Access across jurisdictions

The availability, classification, permitted promotion and lawful use of a product or service depend on the applicable jurisdiction, its intended use and the provider’s authorisations. A publication, registration, research permission or approval in one country does not establish authorisation in another. Website access, an enquiry or a newsletter subscription does not establish eligibility for a service or participation in a clinical study.

Before arranging a regulated service, confirm its precise scope, provider credentials and applicable permissions. Visitors should consider the rules of their own jurisdiction and the jurisdiction where a service would be delivered. Providers remain responsible for their own legal and professional obligations.

• United States: consult the FDA’s current product-specific approval information and applicable federal and state requirements. FDA approval is specific to a product and its authorised use. FDA cellular and gene therapy products.
• European Union / EEA: advanced therapy medicinal products fall within the European regulatory framework, with relevant national authorities also playing important roles. Consult the EMA and the competent authority for the country concerned. Other European jurisdictions have their own rules. EMA advanced therapies.
• China: consult the National Medical Products Administration for product registration and marketing requirements, together with the relevant health authorities for medical practice and research. NMPA responsibilities.
• Singapore: HSA regulates cell, tissue and gene therapy products through a risk-based framework, with notification or registration requirements depending on classification. Healthcare and research requirements also apply where relevant. HSA regulatory overview.
• Malaysia: consult the NPRA / Drug Control Authority for the applicable registration framework for cell and gene therapy products, and the relevant Malaysian authorities for services and facilities. NPRA biologics framework.
• Japan: the framework distinguishes the provision and research use of regenerative medicine under the Act on the Safety of Regenerative Medicine from the commercialisation of regenerative medical products under the PMD Act. Confirm the applicable pathway with the provider and relevant authorities. PMDA regenerative medical products.
• Other countries and territories: consult your national medicines regulator, health authority and appropriately qualified local advisers. The jurisdictions above are examples, not an exhaustive statement of applicable law.

Imagery, heritage and partnerships

Heritage references express design inspiration and cultural perspective. Stock photography, commissioned visualisations, fictional campaign portraits and AI-generated imagery are illustrative unless specifically identified as photographs of Noah Thera facilities, personnel or clients. They do not establish clinical outcomes or endorsements. Campus concepts and proposed equipment are subject to project development and confirmed availability.

References to publications, universities, hospitals, regulators, technologies or countries acknowledge their work or provide context. They do not imply a formal partnership, accreditation or endorsement unless expressly identified and supported. Any commercial or investment discussion is subject to separate written information and applicable requirements; website content is not a securities offer or a promise of financial returns.

Your information

Please use our contact page for general enquiries and our privacy notice for information about personal data. Avoid submitting medical records, genetic data or other sensitive information through a general enquiry or newsletter form. Newsletter subscription does not create a clinician–patient relationship. You can unsubscribe using the link in each issue.

Updated 18 September 2026.